|
Recommendations
|
Loop Capital analyst Alan… ShowHide Related Items >><< - 01/25/21
- AMC Entertainment jumps 31% to $4.59 after announcing $917M capital raise
- 01/25/21
- AMC Entertainment raises $917M of fresh investment capital since mid-December
- 01/25/21
- AMC Entertainment raises $917M of fresh investment capital since mid-December
- 12/22/20
- Sony Pictures CEO says 'don't think' will move to 'day and date' film releases
- 08:09 Today B. Riley Securities
- AMC Entertainment price target raised to $5.50 from $3.50 at B. Riley Securities
- 12/28/20 B. Riley Securities
- 'Wonder Women' opens well above expectations, says B. Riley Securities
- 12/04/20 B. Riley Securities
- Theater selloff on Warner Bros. news likely an overreaction, says B. Riley
- 11/03/20 B. Riley Securities
- AMC Entertainment price target lowered to $3.50 from $4.50 at B. Riley Securities
- 11/02/20
- AMC Entertainment reports Q3 adjusted EPS ($5.70), consensus ($4.95)
- 11/02/20
- Notable companies reporting after market close
- 10/20/20
- AMC Entertainment sees Q3 revenue roughly $119.5M, consensus $155.31M
- 08/06/20
- AMC Entertainment reports Q2 adjusted EPS ($5.44), consensus ($4.29)
- 01/06/21
- AMC CEO tells CNBC company still needs to raise $550M this year
- 12/11/20
- Apollo, others offered debt to AMC in Chapter 11 deal, NY Post reports
- 10/18/20
- NY state moves to reopen movie theaters, ski resorts, Bloomberg reports
- 10/14/20
- AMC Entertainment denies bankruptcy rumors, Reuters reports
- 01/25/21
- Fly Intel: Wall Street's top stories for Monday
- 01/25/21
- Fly Intel: Pre-market Movers
- 12/28/20
- Fly Insider:180 Degree Capital, AMC among week's notable insider trades
- 12/28/20
- AMC, Cinemark rise as WW84 scores highest box office opening of pandemic
- 08:55 Today
- Notable open interest changes for January 26th
- 01/20/21
- Unusual call flow in option market yesterday
- 01/19/21
- Option traders line up in AMC Entertainment as shares jump 28%
- 01/06/21
- Largest borrow rate increases among liquid names
|
|
Conference/Events
| ShowHide Related Items >><< - 01/25/21
- AbbVie announces EC approval of Rinvoq for PsA and ankylosing spondylitis
- 01/25/21
- Alector doses first patient in Phase 2 study of AL002 in Alzheimer's
- 01/13/21
- Genmab achieves $40M milestone in AbbVie collaboration
- 01/12/21
- Immunovant appoints Rita Jain as Chief medical Officer
- 01/13/21
- Alexion further pauses global Phase 3 study of Ultomiris
- 01/13/21
- Alexion to pause further enrollment in Phase 3 study of ULTOMIRIS
- 12/13/20
- Fly Intel: Top five weekend stock stories
- 12/12/20
- AstraZeneca sees 'robust and sustainable' core EPS accretion from Alexion deal
- 06:07 Today
- AstraZeneca's Symbicort Turbuhaler approved in China for mild asthma
- 01/25/21
- Minnesota DOH reports first U.S. case of COVID-19 variant first found in Brazil
- 01/25/21
- AstraZeneca's Calquence approved in Japan for CLL treatment
- 01/25/21
- AstraZeneca's Calquence met primary endpoint in head-to-head trial vs. ibrutinib
- 01/11/21
- AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint
- 01/11/21
- Biogen study to develop biomarkers of cognitive health using Apple devices
- 01/08/21
- Biogen treats first patient in RESPOND study of SPINRAZA
- 01/05/21
- Biogen, ViGeneron enter collaboration agreement to develop gene therapy products
- 01/22/21
- Bristol-Myers announces approval of Opdivo plus Cabometyx for carcinoma
- 01/20/21
- Bristol-Myers: FDA accepts for Priority Review sBLA for Opdivo combination
- 01/11/21
- Bristol-Myers CEO: Our strategy for growth is based on innovation
- 01/11/21
- Illumina announces new and expanded oncology partnerships
- 12/16/20
- Merck, Eisai: KEYTRUDA plus LENVIMA showed significant improvement in OS
- 12/10/20
- Biogen submits aducanumab J-NDA to Ministry of Health, Labor and Welfare
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 01/15/21
- Halozyme says Janssen receives FDA approval of Darzalex Faspro
- 12/23/20
- Halozyme announces EC approval of Roche fixed-dose combination with Enhanze
- 12/07/20
- Halozyme's Kelly sells 35,086 common shares
- 12/02/20
- Halozyme's Kelley sells 31,792 common shares
- 12/21/20
- Q2 Solutions teams with Adaptive Biotechnologies to market immunoSEQ Assay
- 12/16/20
- Iqvia in pact with Servier to 'reinvent' its R&D clinical development processes
- 11/18/20
- Iqvia's Rittenmeyer sells over 40,000 common shares
- 11/13/20
- Third Point takes stake in PG&E, boosts Alibaba stake, exits Baxter
- 07:24 Today
- AbCellera announces results from BLAZE-1 trial with Eli Lilly
- 06:54 Today
- Eli Lilly announces BLAZE-1 trial meets primary endpoint
- 01/22/21
- Eli Lilly completes acquisition of Prevail Therapeutics
- 01/21/21
- AbCellera-discovered antibody prevented COVID-19 in nursing homes, reduced risks
- 01/25/21
- LinkedIn names Dan Shapero as first ever COO
- 01/22/21
- Microsoft increases pricing for Xbox Live Gold
- 01/22/21
- SAP, Microsoft expand partnership
- 01/20/21
- EU fines Valve, Capcom, ZeniMax, others EUR7.8M for 'geo-blocking' practices
- 01/06/21 RBC Capital
- AbbVie named one of top stocks to own in 2021 by RBC Capital
- 12/17/20 Stifel
- Outcome in Evolus IP case 'better than most investors expected,' says Stifel
- 12/16/20 SVB Leerink
- AbbVie price target raised to $128 from $119 at SVB Leerink
- 12/15/20 Mizuho
- AbbVie price target raised to $117 from $111 at Mizuho
- 01/08/21 Raymond James
- Alexion downgraded to Market Perform from Outperform at Raymond James
- 12/16/20 Truist
- Alexion downgraded to Hold from Buy at Truist
- 12/15/20 Truist
- Argenx price target raised to $350 from $275 at Truist
- 12/14/20 Citi
- Alexion downgraded to Neutral from Buy at Citi
- 01/22/21 Barclays
- AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays
- 01/19/21 BTIG
- Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
- 01/15/21 Berenberg
- AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
- 01/15/21
- Fly Intel: Top five analyst initiations
- 01/14/21 Truist
- Truist says FDA wouldn't be discussing label if not going to approve aducanumab
- 01/11/21 Goldman Sachs
- Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
- 12/04/20 Mizuho
- Sage Therapeutics upgraded to Buy from Neutral at Mizuho
- 12/01/20 Truist
- Sage Therapeutics price target raised to $70 from $60 at Truist
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 01/20/21 Citi
- Citi opens 'negative Catalyst Watch' on Bristol-Myers
- 12/15/20 Goldman Sachs
- Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
- 12/09/20 Mizuho
- Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 01/25/21 BMO Capital
- Halozyme price target raised to $65 from $56 at BMO Capital
- 01/21/21 Benchmark
- Halozyme price target raised to $59 from $46 at Benchmark
- 01/14/21 Piper Sandler
- Halozyme price target raised to $50 from $42 at Piper Sandler
- 01/11/21 Benchmark
- Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
- 12/18/20 Mizuho
- Iqvia price target raised to $200 from $190 at Mizuho
- 10/22/20 Deutsche Bank
- Iqvia price target raised to $196 from $180 at Deutsche Bank
- 10/21/20 UBS
- Iqvia price target raised to $224 from $204 at UBS
- 10/21/20 Morgan Stanley
- Iqvia price target raised to $195 from $182 at Morgan Stanley
- 01/20/21 Citi
- Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
- 01/19/21 Roth Capital
- Merus price target raised to $32 from $19 at Roth Capital
- 01/19/21
- Fly Intel: Top five analyst upgrades
- 01/19/21 Mizuho
- Eli Lilly upgraded to Buy from Neutral at Mizuho
- 01/25/21 Raymond James
- Microsoft assumed with a Strong Buy at Raymond James
- 01/25/21 Morgan Stanley
- Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
- 01/25/21 DA Davidson
- Box downgraded to Neutral from Buy at DA Davidson
- 01/22/21 RBC Capital
- Varonis price target raised to $200 from $165 at RBC Capital
- 10/30/20
- AbbVie sees Q4 adjusted EPS $2.83-$2.85, consensus $2.90
- 10/30/20
- AbbVie raises FY20 revenue view to ~$45.7B from ~$45.5B, consensus $45.48B
- 10/30/20
- AbbVie raises FY20 adj. EPS view to $10.47-$10.49 from $10.35-$10.45
- 10/30/20
- AbbVie reports Q3 adjusted EPS $2.83, consensus $2.76
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 10/28/20
- Notable companies reporting before tomorrow's open
- 10/28/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
- 11/05/20
- AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year
- 07/30/20
- AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS
- 07/30/20
- AstraZeneca reports Q2 core EPS 96c, up 31% at CER
- 10/21/20
- Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00
- 10/21/20
- Biogen reports Q3 adjusted EPS $8.84, consensus $8.13
- 10/20/20
- Notable companies reporting before tomorrow's open
- 10/20/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 01/11/21
- Halozyme sees FY21 GAAP EPS $1.40-$1.55, consensus $1.79
- 11/23/20
- Halozyme raises FY20 EPS view to 90c-95c from 80c-85c, consensus 86c
- 11/02/20
- Halozyme raises FY20 GAAP EPS view to 80c-85c from 60c-75
- 11/02/20
- Halozyme reports Q1 EPS 25c, consensus 19c
- 10/20/20
- Iqvia sees FY21 EPS $7.65-$7.95, consensus $7.57
- 10/20/20
- Iqvia sees Q4 EPS $1.93 - $2.03, consensus $1.97
- 10/20/20
- Iqvia raises FY20 EPS view to $6.25 - $6.35 from $6.10 - $6.30, consensus $6.18
- 10/20/20
- Iqvia reports Q3 EPS $1.63, consensus $1.52
- 12/15/20
- Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07
- 12/15/20
- Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32
- 12/02/20
- Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c
- 10/27/20
- Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28
- 10/27/20
- Microsoft sees Q2 Productivity and Business Processes revenue $12.75B-$13B
- 10/27/20
- Microsoft reports Q1 EPS $1.82, consensus $1.54
- 10/27/20
- Notable companies reporting after market close
- 12/16/20
- AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says
- 12/16/20
- AbbVie unit wins ITC trade secret case against Evolus, Bloomberg says
- 12/09/20
- Former Allergan CEO's SPAC to merge with HydraFacial Co, WSJ reports
- 12/04/20
- Ironwood adds 'serial seller' to board, Dealreporter says
- 10/09/20
- Betaville says Vertex, Sanofi seen as interested in Alexion, Bloomberg reports
- 01/25/21
- EU urges AstraZeneca to accelerate COVID vaccine deliveries, Reuters reports
- 01/24/21
- Germany expects AstraZeneca to deliver 3M vaccine doses in February,Reuters says
- 01/22/21
- AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says
- 01/22/21
- EU to see delay of AstraZeneca COVID vaccine delivery, FT reports
- 11/07/20
- Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says
- 11/07/20
- FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says
- 09/28/20
- Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says
- 09/28/20
- Biogen loses appeal ruling on MS drug Rebif, Bloomberg says
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 10/05/20
- Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports
- 12/30/20
- Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 01/22/21
- YouTube enables HDR support on Xbox gaming systems, Verge reports
- 01/19/21
- FireEye releases tool for auditing networks after SolarWinds hack, ZDNet says
- 01/14/21
- IBM buying cloud computing consultant Taos Mountain, WSJ reports
- 01/13/21
- Lucasfilm partners with Ubisoft to make open-world 'Star Wars' game, Wired says
- 11/18/20
- Tesla, Boeing upgrades among today's top calls on Wall Street
- 11/17/20
- Fly Intel: Wall Street's top stories for Tuesday
- 09/29/20
- Hersey, Best Buy upgrades among today's top calls on Wall Street
- 09/04/20
- Fly Intel: Wall Street's top stories for Friday
- 12/14/20
- Fly Intel: Wall Street's top stories for Monday
- 12/14/20
- Fly Intel: Wall Street's top stories at midday
- 12/14/20
- Fly Intel: Pre-market Movers
- 12/07/20
- Fly Insider: Foot Locker, Alexion among weeks notable insider trades
- 12/30/20
- Fly Intel: Wall Street's top stories for Wednesday
- 12/30/20
- Fly Intel: Wall Street's top stories at midday
- 12/30/20
- AstraZeneca upgrade, Spotify target change among top calls on Wall Street
- 12/30/20
- Fly Intel: Pre-market Movers
- 01/11/21
- Fly Intel: Wall Street's top stories for Monday
- 01/11/21
- Fly Intel: Wall Street's top stories at midday
- 01/11/21
- Eli Lilly and Alzheimer's research peers jump after study meets endpoint
- 12/04/20
- Delta, United, Boeing downgrades among today's top calls on Wall Street
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 11/21/20
- Week in review: How Trump's policies moved stocks
- 11/05/20
- Fly Intel: Pre-market Movers
- 10/08/20
- Cytokinetics plunges following mixed results from heart drug trial
- 08/07/20
- Fly Intel: Wall Street's top stories at midday
- 11/05/20
- Fly Intel: After-Hours Movers
- 11/02/20
- Fly Intel: After-Hours Movers
- 08/10/20
- Fly Intel: After-Hours Movers
- 10/20/20
- Fly Intel: Pre-market Movers
- 01/21/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/21/21
- Fly Intel: Wall Street's top stories at midday
- 01/11/21
- Fly Intel: Wall Street's top stories for Monday
- 01/11/21
- Fly Intel: Wall Street's top stories at midday
- 01/25/21
- GameStop jumps above $100 in volatile trading despite double downgrade to sell
- 01/22/21
- Disney, Ford upgrades among today's top calls on Wall Street
- 01/19/21
- Fly Intel: Wall Street's top stories for Tuesday
- 01/19/21
- Fly Intel: Wall Street's top stories at midday
- 09/15/20
- Alexion strength attributed to takeover speculation
- 09/15/20
- Alexion strength attributed to takeover speculation
- 11/10/20
- AbbVie call volume above normal and directionally bullish
- 11/04/20
- Unusually active option classes on open November 4th
- 10/30/20
- Unusually active option classes on open October 30th
- 10/16/20
- AbbVie call volume above normal and directionally bullish
- 12/14/20
- Early notable gainers among liquid option names on December 14th
- 10/20/20
- Alexion call volume above normal and directionally bullish
- 10/19/20
- Alexion call volume above normal and directionally bullish
- 09/11/20
- Alexion call volume above normal and directionally bullish
- 12/30/20
- Unusually active option classes on open December 30th
- 12/29/20
- Unusually active option classes on open December 29th
- 12/28/20
- Unusually active option classes on open December 28th
- 12/14/20
- AstraZeneca call volume above normal and directionally bullish
- 01/08/21
- Biogen put volume heavy and directionally bearish
- 11/11/20
- Early notable gainers among liquid option names on November 11th
- 11/05/20
- Unusually active option classes on open November 5th
- 09/28/20
- Early notable gainers among liquid option names on September 28th
- 01/20/21
- Unusually active option classes on open January 20th
- 01/11/21
- Unusually active option classes on open January 11th
- 01/05/21
- Bristol Myers Squibb call volume above normal and directionally bullish
- 01/04/21
- Bristol Myers Squibb call buyer realizes 25% same-day gains
- 01/15/21
- Eli Lilly call volume above normal and directionally bullish
- 01/13/21
- Early notable gainers among liquid option names on January 13th
- 01/11/21
- Early notable gainers among liquid option names on January 11th
- 12/09/20
- Early notable gainers among liquid option names on December 9th
- 12/17/20
- Notable open interest changes for December 17th
- 11/11/20
- Notable open interest changes for November 11th
- 10/28/20
- Notable open interest changes for October 28th
- 10/27/20
- Notable open interest changes for October 27th
|